The economics of adalimumab for ulcerative colitis

被引：1

作者：

Xie, Feng ^{[1
]}

机构：

[1] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 4A6, Canada

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2015年 / 15卷 / 03期

关键词：

adalimumab; cost-effectiveness; economics; infliximab; ulcerative colitis; MAINTENANCE THERAPY; INDUCTION THERAPY; LOST RESPONSE; OPEN-LABEL; INFLIXIMAB; EFFICACY; INTOLERANCE; MODERATE; METAANALYSIS; REMISSION;

D O I：

10.1586/14737167.2015.1031113

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Ulcerative colitis is a chronic inflammatory disease, characterized by diffuse mucosal inflammation in the colon. Adalimumab, as a TNF- blocker, offers a safe and efficacious treatment option for patients with moderate to severe ulcerative colitis and refractory or intolerant to conventional medications; however, its cost-effectiveness profile has not yet been well established. Future economic evaluations should choose appropriate comparators in the context of target-reimbursement decision making and focus on cost-effectiveness over a long time horizon.

引用

页码：373 / 377

页数：5

共 50 条

[41] Histological Remission in Ulcerative Colitis in Deep Remission under Treatment with Adalimumab
Tursi, Antonio
Nenna, Rosanna
Musci, Giovanni
Elisei, Walter
Picchio, Marcello
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2021, 30 (01) : 55 - 58
[42] Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Xie F.
Blackhouse G.
Assasi N.
Gaebel K.
Robertson D.
Goeree R.
Cost Effectiveness and Resource Allocation, 7 (1)
[43] Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up
Chandra, Alok
Kanth, Ravi
Thareja, Sandeep
BIOLOGICS-TARGETS & THERAPY, 2019, 13 : 191 - 200
[44] Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis
Salman, Ahmed
Salman, Mohamed A.
Elewa, Ahmed
Awwad, Asmaa M.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
[45] Ulcerative colitis - treatment with biologicals
Teixeira, Fabio Vieira
Vilela, Eduardo Garcia
Mourao Cintra Damiao, Aderson Omar
Vieira, Andrea
De Albuquerque, Idblan Carvalho
Luz Parente, Jose Miguel
Fonseca Chebli, Julio Maria
Ambrogini Junior, Orlando
Hossne, Rogerio Saad
Miszputen, Sender Jankiel
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2019, 65 (04): : 547 - 553
[46] Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study
Christensen, Katrine Risager
Steenholdt, Casper
Brynskov, Jorn
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2015, 50 (08) : 1018 - 1024
[47] Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States
Sandborn, William J.
Sakuraba, Atsushi
Wang, Anthony
Macaulay, Dendy
Reichmann, William
Wang, Song
Chao, Jingdong
Skup, Martha
CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (07) : 1233 - 1241
[48] The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
Ye, Byong Duk
Cheon, Jae Hee
Song, Ki Hwan
Kim, Joo Sung
Kim, Young-Ho
Yoon, Hyuk
Lee, Kang-Moon
Kang, Sang-Bum
Jang, Byung Ik
Park, Jae Jun
Kim, Tae Oh
Lee, Dae-Wook
Foo, Chee Yoong
Shin, Jeong Eun
Park, Dong Il
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
[49] Current position on Vedolizumab for ulcerative colitis and Crohn's disease
Schreiber, S.
Dignass, A. U.
Hartmann, H.
Kruis, W.
Rogler, G.
Siegmund, B.
Stallmach, A.
Witte, C.
Bokemeyer, B.
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (06): : 591 - 602
[50] Overview of Biological Therapy in Ulcerative Colitis: Current and Future Directions
Furfaro, Federica
Bezzio, Cristina
Ardizzone, Sandro
Massari, Alessandro
de Franchis, Roberto
Maconi, Giovanni
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2015, 24 (02) : 203 - 213

← 1 2 3 4 5 →